{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:13:43Z","timestamp":1793110423991,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Since computed tomography (CT) is a part of standard diagnostic protocol in pancreatic ductal adenocarcinoma (PDAC), we have evaluated the value of CT for sarcopenia screening in patients with PDAC, intending to expand the diagnostic value of tomographic studies. In our study, we included 177 patients with available CT images. Two groups were formed: Group 1 consisted of 117 patients with PDAC in various locations and stages and Group 2, or the control group, consisted of 60 \"nominally healthy\" patients with other somatic non-oncological diseases. The body mass index (BMI) was defined as a ratio of patient\u2019s weight to the square of their height (kg\/m<jats:sup>2<\/jats:sup>). CT-based body composition analysis was performed using commercially available software with evaluation of sarcopenia using skeletal muscle index (SMI, cm<jats:sup>2<\/jats:sup>\/m<jats:sup>2<\/jats:sup>). Based on the SMI values, sarcopenia was found in 67.5% of patients (79 out of 117) in the first patient group. It was found more frequently in males (42 out of 56; 75%) than in females (37 out of 61; 60.6%). Additionally, we observed a decrease in muscle mass (hidden sarcopenia) in 79.7% in patients with a normal BMI. Even in overweight patients, sarcopenia was found in 50% (sarcopenic obesity). In patients with reduced BMI sarcopenia was found in all cases (100%). Statistically significant difference of SMI between two groups was revealed for both sexes (p = 0,0001), with no significant difference between groups in BMI. BMI is an inaccurate value for the assessment of body composition as it does not reflect in the details the human body structure. As SMI may correlate with the prognosis, decreased muscle mass- especially \"hidden\" sarcopenia or sarcopenic obesity- should be reported. The use of CT-based evaluation of sarcopenia and sarcopenic obesity will allow for a better treatment response assessment in patients with cancer cachexia.<\/jats:p>","DOI":"10.1371\/journal.pone.0291185","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T18:29:33Z","timestamp":1706207373000},"page":"e0291185","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-5204","authenticated-orcid":true,"given":"Ekaterina","family":"Khristenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5649-2193","authenticated-orcid":true,"given":"Valentin","family":"Sinitsyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Rieden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker","family":"Girod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Kauczor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-1594","authenticated-orcid":true,"given":"Philipp","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Klauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Lyadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"pone.0291185.ref001","doi-asserted-by":"crossref","first-page":"S1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"S. Antoun","year":"2010","journal-title":"Annals of Oncology"},{"key":"pone.0291185.ref002","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13539-011-0031-9","article-title":"Pitfalls in defining and quantifying cachexia.","volume":"2","author":"V.E. Baracos","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5 Suppl","key":"pone.0291185.ref003","doi-asserted-by":"crossref","first-page":"990S","DOI":"10.1093\/jn\/127.5.990S","article-title":"Sarcopenia: origins and clinical relevance","volume":"127","author":"I.H. Rosenberg","year":"1997","journal-title":"J Nutr"},{"issue":"4","key":"pone.0291185.ref004","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people.","volume":"39","author":"A.J. Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"issue":"4","key":"pone.0291185.ref005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jamda.2011.01.003","article-title":"Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia.","volume":"12","author":"R.A. Fielding","year":"2011","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"pone.0291185.ref006","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/gerona\/glu010","article-title":"The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates","volume":"69","author":"S.A. Studenski","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"pone.0291185.ref007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis.","volume":"48","author":"A.J. Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"1","key":"pone.0291185.ref008","first-page":"19","article-title":"Pancreatology.","volume":"15","author":"I. Ozola Zalite","year":"2015","journal-title":"Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review."},{"key":"pone.0291185.ref009","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1532-5415.2002.50216.x","article-title":"Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability.","volume":"50","author":"I. Janssen","year":"2002","journal-title":"J. Am. Geriatr. Soc."},{"key":"pone.0291185.ref010","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-09-1525","article-title":"Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer","volume":"15","author":"B.H. Tan","year":"2009","journal-title":"Clin. Cancer"},{"key":"pone.0291185.ref011","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1017\/BJN20061943","article-title":"Sarcopenia is predictive of nosocomial infection in care of the elderly","volume":"96","author":"G. Cosqueric","year":"2006","journal-title":"Br. J. Nutr"},{"key":"pone.0291185.ref012","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/SPC.0b013e32834c49eb","article-title":"The advantages and limitations of cross-sectional body composition analysis.","volume":"5","author":"A.J. Mac Donald","year":"2011","journal-title":"Current Opinion in Supportive and Palliative Care."},{"key":"pone.0291185.ref013","first-page":"69","article-title":"The emerging role of computerized tomography in assessing cancer cachexia","volume":"3","author":"C.M.M. Prado","year":"2009","journal-title":"Current Opinion in Supportive and Palliative Care"},{"key":"pone.0291185.ref014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00280-010-1288-y","article-title":"An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity","volume":"67","author":"C.M.M. Prado","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"pone.0291185.ref015","first-page":"264","article-title":"Body composition as an independent determinant of 5-Fluorouracil-based chemotherapy toxicity","volume":"13","author":"C.M.M. Prado","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"pone.0291185.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-061509-131248","article-title":"Muscle wasting in cancer cachexia: clinical implications, diagnosis and emerging treatment strategies.","volume":"62","author":"S. Dodson","year":"2011","journal-title":"Ann. Rev. Med."},{"issue":"8","key":"pone.0291185.ref017","article-title":"Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment","volume":"15","author":"C.M.M. Prado","year":"2009","journal-title":"Cancer Res"},{"issue":"suppl","key":"pone.0291185.ref018","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3945\/ajcn.2010.28608C","article-title":"Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis","volume":"91","author":"V.E. Baracos","year":"2010","journal-title":"J. Clin. Nutr"},{"issue":"4","key":"pone.0291185.ref019","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jamda.2010.02.004","article-title":"Consensus on cachexia definitions.","volume":"11","author":"J.M. Argil\u00e9s","year":"2010","journal-title":"J. Am. Med. Dir. Assoc"},{"key":"pone.0291185.ref020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","author":"C.M.M. Prado","year":"2008","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0291185.ref021","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4251\/wjgo.v11.i7.527","article-title":"Sarcopenia in pancreatic cancer\u2014effects on surgical outcomes and chemotherapy.","volume":"11","author":"M.Y. Chan","year":"2019","journal-title":"World J Gastrointest Oncol."},{"key":"pone.0291185.ref022","article-title":"Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review.","author":"L.M. Donini","year":"2019","journal-title":"Clin Nutr."},{"key":"pone.0291185.ref023","first-page":"1061","article-title":"Visceral Adipose Tissue and Skeletal Muscle Index Distribution Predicts Severe Pancreatic Fistula Development After Pancreaticoduodenectomy","volume":"38","author":"H. Yamane","year":"2018","journal-title":"Anticancer Res"},{"key":"pone.0291185.ref024","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.nut.2016.04.002","article-title":"A high visceral adipose tissue-to-skeletal muscle ratio as a determinant of major complications after pancreatoduodenectomy for cancer","volume":"32","author":"M. Sandini","year":"2016","journal-title":"Nutrition"},{"key":"pone.0291185.ref025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpainsymman.2011.09.010","article-title":"Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study","volume":"44","author":"S. Dalal","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"pone.0291185.ref026","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jcsm.12307","article-title":"Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer","volume":"9","author":"J.K. Kays","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"pone.0291185.ref027","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pan.2017.02.002","article-title":"Impact of body fat and muscle distribution on severity of acute pancreatitis.","volume":"17","author":"S.B. Yoon","year":"2017","journal-title":"Pancreatology"},{"key":"pone.0291185.ref028","article-title":"Automated body composition analysis of clinically acquired computed tomography scans using neural networks.","author":"M.T. Paris","year":"2020","journal-title":"Clin Nutr."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T18:29:57Z","timestamp":1706207397000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291185"}},"subtitle":[],"editor":[{"given":"Shuai","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0291185","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}